Biology of tumor necrosis factor-α - Implications for psoriaris

Experimental Dermatology

Volumn 13, Issue 4, 2004, Pages 193-222

  Schottelius, Arndt J G ^a   Moldawer, Lyle L ^b   Dinarello, Charles A ^c   Asadullah, Khusru ^d   Sterry, Wolfram ^e   Edwards III, Carl K ^a  

^a BAYER AG   (Germany)

^b UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

^c UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

^d BAYER PHARMA AG   (Germany)

^e CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

Biologicals; Cytokines; Immunotherapy; Inflammatory skin diseases; Psoriasis; TNF

Indexed keywords

ADALIMUMAB; ANTIRHEUMATIC AGENT; CERTOLIZUMAB PEGOL; CYCLOSPORIN A; ETANERCEPT; HYDROXYCHLOROQUINE; INFLIXIMAB; LENERCEPT; METHOTREXATE; NEUTRALIZING ANTIBODY; ONERCEPT; PEGSUNERCEPT; PLACEBO; PREDNISONE; PROTEIN P55; T LYMPHOCYTE ANTIBODY; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR ALPHA ANTIBODY; TUMOR NECROSIS FACTOR ALPHA RECEPTOR; TUMOR NECROSIS FACTOR RECEPTOR; UNCLASSIFIED DRUG;

CIRCULATION; DATA ANALYSIS; DRUG ACTIVITY; DRUG STRUCTURE; GENE EXPRESSION REGULATION; GENE OVEREXPRESSION; HOST RESISTANCE; HUMAN; IMMUNOPATHOLOGY; INFLAMMATION; INJECTION SITE; NONHUMAN; PROTEIN EXPRESSION; PROTEIN SYNTHESIS; PSORIASIS; RECEPTOR BINDING; REVIEW; SIGNAL TRANSDUCTION; SKIN DEFECT; SKIN MANIFESTATION;

ANIMALS; ANTIBODIES, MONOCLONAL; AUTOIMMUNE DISEASES; GENE EXPRESSION REGULATION; HUMANS; MODELS, IMMUNOLOGICAL; PSORIASIS; RECEPTORS, TUMOR NECROSIS FACTOR; RECOMBINANT PROTEINS; SIGNAL TRANSDUCTION; T-LYMPHOCYTE SUBSETS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 2442443310     PISSN: 09066705     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.0906-6705.2004.00205.x     Document Type: Review

References (170)

1. Abrams J R, Kelley S L, Hayes E et al. Blockade of T lymphocyte costimulation with cytotoxic T lymphocyte-associated antigen 4-immunoglobulin (CTLA4Ig) reverses the cellular pathology of psoriatic plaques, including the activation of keratinocytes, dendritic cells, and endothelial cells. J Exp Med 2000: 192: 681-694.
2. Abrams J R, Lebwohl M G, Guzzo C A et al. CTLA41g mediated blockade of T-cell costimulation in patients with psoriasis vulgaris. J Clin Invest 1999: 103: 1243-1252.
3. Asadullah K, Docke W D, Ebeling M et al. Interleukin 10 treatment of psoriasis: clinical results of a phase 2 trial. Arch Dermatol 1999: 135: 187-192.
4. Asadullah K, Volk H D, Sterry W. Novel immunotherapies for psoriasis. Trends Immunol 2002: 23: 47-53.
5. Baker B S, Fry L. The immunology of psoriasis. Br J Dermatol 1992: 126: 1-9.
6. Haranaka K, Carswell E A, Williamson B D, Prendergast J S, Satomi N, Old L J. Purification, characterization, and antitumor activity of nonrecombinant mouse tumor necrosis factor. Proc Natl Acad Sci USA 1986: 83: 3949-3953.
7. Aggarwal B B, Aiyer R A, Pennica D, Gray P W, Groeddel D V. Human tumour necrosis factor: structure and receptor interactions. Ciba Found Symp 1987: 131: 39-51.
8. Pennica D, Hayflick J S, Bringman T S, Palladino M A, Goeddel D V. Cloning and expression in Escherichia coli of the cDNA for murine tumor necrosis factor. Proc Natl Acad Sci USA 1985: 82: 6060-6064.
9. Beutler B. Tumor Necrosis Factors. The Molecules and Their Emerging Role in Medicine. New York, NY: Raven Press, 1992.
10. Kriegler M, Perez C, DeFay K, Albert I, Lu S D. A novel form of TNF/cachectin is a cell surface cytotoxic transmembrane protein: ramifications for the complex physiology of TNF. immune responses in MHC class II-deficient mice. Cell 1988: 53: 45-53.
11. Moss M L, Jin S L C, Milla M E et al. Cloning of a disintegrin metalloproteinase that processes precursor tumor-necrosis factor-alpha. Nature 1997: 385: 733-736.
12. Peschon J J, Slack J L, Reddy P et al. An essential role for ectodomain shedding in mammalian development. Science 1998: 282: 1281-1284.
13. Bazzoni F, Beutler B. The tumor necrosis factor ligand and receptor families. N Engl J Med 1996: 334: 1717-1725.
14. Beutler B, Brown T. Polymorphism of the mouse TNF-alpha locus: sequence studies of the 3′-untranslated region and first intron. Gene 1993: 129: 279-283.
15. Han J, Brown T, Beutler B. Endotoxin-responsive sequences control cachectin/turnor necrosis factor biosynthesis at the translational level. J Exp Med 1990: 171: 465-475.
16. Piecyk M, Wax S, Beck A R et al. TIA-1 is a translational silencer that selectively regulates the expression of TNF-alpha. EMBO J 2000: 19 (15): 4154-4163.
17. Kontoyiannis D, Pasparakis M, Pizarro T T, Cominelli F, Kollias G. Impaired on/off regulation of TNF biosynthesis in mice lacking TNF AU-rich elements: implications for joint and gut-associated immunopathologies. Immunity 1999: 10: 387-398.
18. Schottelius A J, Mayo M W, Sartor R B, Baldwin A S J. Interleukin-10 signaling blocks inhibitor of kappaB kinase activity and nuclear factor kappaB DNA binding. J Biol Chem 1999: 274 (45): 31868-31874.
19. Wong B, Choi Y. Pathways leading to cell death in T cells. Curr Opin Immunol 1997: 9: 358-364.
20. Butler D M, Malfait A, Mason L J et al. DBA/1 mice expressing the human TNF-alpha transgene develop a severe, erosive arthritis. J Immunol 1997: 159 (6): 2867-2876.
21. Alexopoulou L, Pasparakis M, Kollias G. A murine transmembrane tumor necrosis factor transgene induces arthritis by cooperative p55/p75 tumor necrosis factor receptor signaling. Eur J Immunol 1997: 27 (10): 2588-2592.
22. TgA86) mice injected with mycoplasma pulmonies or mycoplasma arthritidis. Arthritis Rheum 1999: 42: S120.
23. Marinova-Mutafchieva L, Williams R O, Masoon L J Mauri C, Feldmann M, Maini R N. Dynamics of proinflammatory cytokine expression in the joints o mice with collagen-induced arthritis (CIA). Clin Exp Immunol 1997: 107: 507-512.
24. Mussener A, Litton M J, Lindros E, Klareskog L. Cytokine production in synovial tissue of mice with collagen-induced arthritis (CIA). Clin Exp Immunol 1997: 107: 485-493.
25. Jeng K C G, Liu M T, Lan J L, Wu C.H, Wong D W, Cheung B M.H. Collagen induces cytokine production by synovial fluid mononuclear cells in rheumatoid arthritis. Immune responses in MHC class II-deficient mice. Immunol Lett 1995: 45: 13-17.
26. Thorbecke G J, Shah R, Leu C.H, Kuruvilla A P, Hardison A M Palladino M A. Involvement of endogenous tumor necrosis factor alpha and transforming growth factor beta during induction of collagen type II arthritis in mice. Proc Natl Acad Sci USA 1992: 89: 7375-7379.
27. Williams R O, Feldmann M, Maini R N. Anti-tumor necrosis factor ameliorates joint disease in murine collagen-induced arthritis. Proc Natl Acad Sci USA 1992: 89: 9784-9788.
28. Piguet P F, Grau G E, Vesin C, Loetscher H, Gentz R, Lesslauer W. Evolution of collagen arthritis in mice is arrested by treatment with anti-tumour necrosis factor (TNF) antibody or a recombinant soluble TNF receptor. Immunology 1992: 77: 510-514.
29. Probert L, Plows D, Kontogeorgos G, Kollias G. The type I interleukin-1 receptor acts in series with tumor necrosis factor (TNF) to induce arthritis in TNF-transgenic mice. Eur J Immunol 1995: 25 (6): 1794-1797.
30. Ulfgren A K, Andersson U, Engstrom M, Klareskog L, Maini R N, Taylor P C. Systemic anti-tumor necrosis factor alpha therapy in rheumatoid arthritis down-regulates synovial tumor necrosis factor alpha synthesis. Arthritis Rheum 2000: 43 (11): 2391-2396.
31. van den Berg W B, Joosten L A, Kollias G, van de Loo F A. Role of tumour necrosis factor alpha in experimental arthritis: separate activity of interleukin 1beta in chronicity and cartilage destruction. Ann Rheum Dis 1999: 58 (Suppl. 1): I40-I48.
32. van den Berg W B. Uncoupling of inflammatory and destructive mechanisms in arthritis. Semin Arthritis Rheum 2001: 30 (5): 7-17.
33. Kuiper S, Joosten L A B, Bendele A M et al. Different roles of tumour necrosis factor a and interleukin 1 in murine streptococcal cell wall arthritis. Cytokine 1998: 10 (9): 690-702.
34. Joosten L A, Helsen M M A, Saxne T, Van-de-Loo F A J, Heinegard D, van-den-Berg W B. IL-1alphabeta blockade prevents cartilage and bone destruction in murine type II collagen-induced arthritis, whereas TNF-alpha blockade only ameliorates joint inflammation. J Immunol 1999: 163 (9): 5049-5055.
35. Joosten L A, Helsen M M A, Vandeloo F A J, Vandenberg W B. Anticytokine Treatment of Established Type II, Collagen-Induced Arthritis In D B A/1 Mice: a comparative study using anti-TNF-alpha, anti-IL-1-alpha/ beta, and IL-1ra. Immune responses in MHC class II-deficient mice. Arthritis Rheum 1996: 39 (5): 797-809.
36. Campbell I K, O'Donnell K, Lawlor K E, Wicks I P. Severe inflammatory arthritis and lymphadenopathy in the absence of TNF. J Clin Invest 2001: 107 (12): 1519-1527.
37. van der Poll T, van Deventer S J, Hack C E et al. Effects of leukocytes after injection of tumor necrosis factor into healthy humans. Blood 1992: 79: 693-698.
38. van der Poll T, van Deventer S J, Buller H R, Sturk A, ten Cate J W. Comparison of the early dynamics of systemic prostacyclin release after administration of tumor necrosis factor and endotoxin to healthy humans. J Infect Dis 1991: 164: 599-601.
39. van der Poll T, Romijn J A, Endert E, Borm J J, Buller H R, Sauerwein H P. Tumor necrosis factor mimics the metabolic response to acute infection in health humans. Am J Physiol 1991: 261: E457-E465.
40. van der Poll T, Levi M, Buller H R et al. Fibrinolytic response to tumor necrosis factor in healthy subjects. J Exp Med 1991: 174: 729-732.
41. Spriggs D R, Sherman M L, Michie H et al. Recombinant human tumor necrosis factor administered as a 24-hour intravenous infusion. A phase I and pharmacologic study. J Natl Cancer Inst 1988: 80 (13): 1039-1044.
42. Zamkoff K W, Newman N B, Rudolph A R, Young J, Poiesz B J. A phase I trial of subcutaneously administered recombination tumor necrosis factor to patients with advanced malignancy. J Biol Response Mod 1989: 8 (5): 539-552.
43. Aderka D, Sorkine P, Abu-Abeid S et al. Shedding kinetics of soluble tumor necrosis factor (TNF) receptors after systemic TNF leaking during isolated limb perfusion. Relevance to the pathophysiology of septic shock. J Clin Invest 1998: 101: 650-659.
44. Zwaveling J H, Maring J K, Clarke F L et al. High plasma tumor necrosis factor (TNF)-alpha concentrations and a sepsis-like syndrome in patients undergoing hyperthermic isolated limb perfusion with recombinant TNF-alpha, interferon-gamma, and melphalan. Crit Care Med 1996: 24: 765-770.
45. Edwards C K. III PEGylated recombinant human soluble tumour necrosis factor receptor type I (r-HusTNF-RI) novel high affinity TNF receptor designed for chronic inflammatory diseases. Ann Rheum Dis 1999: 58 (Suppl. 1): 173-181.
46. Bemelmans M H, Gouma D J, Buurman W A. Tissue distribution and clearance of soluble murine TNF receptors in mice. Cytokine 1994: 6: 608-615.
47. Seckinger P, Isaaz S, Dayer J M. Purification and biologic characterization of a specific tumor necrosis factor alpha inhibitor. J Biol Chem 1989: 264: 11966-11973.
48. Seckinger P, Isaaz S, Dayer J M. A human inhibitor of tumor necrosis factor alpha. J Exp Med 1988: 167 (4): 1511-1516.
49. Seckinger P, Zhang J H, Hauptmann B, Dayer J M. Characterization of a tumor necrosis factor alpha (TNF-alpha) inhibitor: evidence of immunological cross-reactivity with the TNF receptor. Proc Natl Acad Sci USA 1990: 87: 5188-5192.
50. Frishman J I, Edwards C K, Sonnenberg M G, Kohno T, Cohen A M, Dinarello C A. Tumor necrosis factor (TNF)-alpha-induced interleukin-8 in human blood cultures discriminates neutralization by the p55 and p75 TNF soluble receptors. J Infect Dis 2000: 182 (6): 1722-1730.
51. Grell M, Wajant H, Zimmerman G, Scheurich P. The type I receptor (CD120a) is the high-affinity receptor for soluble tumor necrosis factor. Proc Natl Acad Sci USA 1998: 95 (2): 570-575.
52. Tartaglia L A, Pennica D, Goeddel D V. Ligand passing: the 75-kd tumor necrosis factor (TNF) receptor recrutits TNF for signaling by the 55 Kd TNF receptor. J Biol Chem 1993: 268 (25): 18542-18548.
53. Grell M, Zimmerman G, Hulser D, Pfizenmaier K, Scheurich P. TNF receptors TR60 and TR80 can mediate apoptosis via induction of distinct signal pathways. J Immunol 1994: 153: 1963-1972.
54. Weiss T, Grell M, Siemienski K et al. TNFR80-dependent enhancement of TNFR60-induced cell death is mediated by TNFR-associated factor 2 and is specific for TNFR60. J Immunol 1998: 161: 3136-3142.
55. Malinin N L, Boldin M P, Kovalenko A V, Wallach D. MAP3K-related kinase involved in NK-κB induction by TNF, CD95 and IL-1. Nature 1997: 385: 540-544.
56. Baeuerle P A, Baltimore D. N F-Kappa-B: ten years after. Cell 1996: 87: 13-20.
57. Wang C Y, Mayo M W, Baldwin A S J. TNF-and cancer therapy-induced apoptosis: potentiation by inhibition of NF-kappaB. Science 1996: 274 (5288): 784-787.
58. Pimentel-Muinos F X, Seed B. Regulated commitment of TNF receptor signaling: a molecular switch for death or activation. Immunity 1999: 11 (6): 783-793.
59. Peschon J J, Torrance D S, Stocking K L et al. TNF receptor-deficient mice reveal divergent roles for p55 and p75 in several models of inflammation. J Immunol 1998: 160: 943-952.
60. Nowak M, Gaines G C, Rosenberg J et al. LPS-induced liver injury in D-galactosamine-sensitized mice requires secreted TNF-alpha and the TNF-p55 receptor. Am J Physiol Regul Integr Comp Physiol 2000: 278 (5): R1202-R1209.
61. Welborn M B, Vanzee K, Edwards P D et al. A Human Tumor Necrosis Factor P75 receptor agonist stimulates in vitro T cell proliferation but does not produce inflammation or shock in the baboon. J Exp Med 1996: 184: 165-171.
62. Van Zee K J, Stackpole S A, Montegut W J et al. A human tumor necrosis factor (TNF) alpha mutant that binds exclusively to the p55 TNF receptor produces toxicity in the baboon. J Exp Med 1994: 179: 1185-1191.
63. Sheehan K C, Pinckard J K, Arthur C D, Dehner L P, Goeddel D V, Schreiber D. Monoclonal antibodies specific for murine p55 and p75 tumor necrosis receptors: identification of a novel in vivo role for p75. J Exp Med 1995: 181: 607-617.
64. Pfeffer K, Matsuyama T, Kuendig T M et al. Mice deficient for the 55 kd tumor necrosis factor receptor are resistant to endotoxic shock, yet succumb to L. monocytogenes infection. Cell 1993: 73: 457-467.
65. Rothe J, Lesslauer W, Loetscher H et al. Mice lacking the tumour necrosis factor receptor 1 are resistant to TNF-mediated toxicity but highly susceptible to infection by Listeria monocytogenes. Nature 1993: 364: 798-802.
66. Erickson S L, de Sauvage F J, Kikly K et al. Decreased sensitivity to tumor-necrosis factor but normal T-cell development in TNF receptor-2-deficient mice. Nature 1994: 372: 560-563.
67. Grell M, Douni E, Wajant H et al. The transmembrane form of tumor necrosis factor is the prime activating ligand of the 8OkDa tumor necrosis factor receptor. Cell 1995: 83: 793-802.
68. Kusters S, Tiegs G, Alexopoulou L et al. In vivo evidence for a functional role of both tumor necrosis factor (TNF) receptors and transmembrane TNF in experimental hepatitis. Eur J Immunol 1997: 27 (11): 2870-2875.
69. Douni E, Kollias G. A critical role of the p75 tumor necrosis factor receptor (p75TNF-R) in organ inflammation independent of TNF, lymphotoxin alpha, of the p55TNF-R. J Exp Med 1998: 188 (7): 1343-1352.
70. Williams L M, Gibbons D L, Gearing A, Maini R N, Feldmann M, Brennan F M. Paradoxical effects of a synthetic metalloproteinase inhibitor that blocks both P55 and P75 TNF receptor shedding and TNFalpha processing in Ra synovial membrane cell cultures. J Clin Invest 1996: 97: 2833-2841.
71. Feldmann M. Development of anti-TNF therapy for rheumatoid arthritis. Nat Rev Immunol 2002: 2 (5): 364-371.
72. Di G F, Nuki G, Duff G W. Tumour necrosis factor in synovial exudates. Ann Rheum Dis 1988: 47: 768-772.
73. Feldmann M, Brennan F M, Maini R N. Role of cytokines in rheumatoid arthritis. Annu Rev Immunol 1996: 14: 397-440.
74. Firestein G S, Alvaro-Garcia J M, Maki R. Quantitative analysis of cytokine gene expression in rheumatoid arthritis. J Immunol 1990: 144: 3347-3353.
75. Chu C Q, Field M, Feldmann M, Maini R N. Localization of tumor necrosis factor alpha in synovial tissues and at the cartilage-pannus junction in patients with rheumatoid arthritis. Arthritis Rheum 1991: 34 (9): 1125.
76. Alvaro-Gracia J M, Zvaifler N J, Brown C B, Kaushansky K, Firestein G S. Cytokines in chronic inflammatory arthritis. VI. Analysis of the synovial cells involved in granulocyte-macrophage colony-stimulating factor production and gene expression in rheumatoid arthritis and its regulation by IL-1 and tumor necrosis factor-alpha. J Immunol 1991: 146 (10): 3365-3371.
77. Alvaro-Gracia J M, Zvaifler N J, Firestein G S. Cytokines in chronic inflammatory arthritis. V. mutual antagonism between interferon-gamma and tumor necrosis factor-alpha on HLA-DR expression, proliferation, collagenase production, and granulocyte macrophage colony-stimulating factor production by rheumatoid arthritis synoviocytes. J Clin Invest 1990: 86 (6): 1790-1798.
78. Alvaro-Gracia J M, Zvaifler N J, Firestein G S. Cytokines in chronic inflammatory arthritis. V. Mutual antagonism between interferon-gamma and tumor necrosis factor-alpha on HLA-DR expression, proliferation, collagenase production, and granulocyte macrophage colony-stimulating factor production by rheumatoid arthritis synoviocytes. J Clin Invest 1990: 86 (6): 1790-1798.
79. Alsalameh S, Winter K, Al-Ward R, Wendler J, Kalden J R, Kinne R W. Distribution of TNF-alpha, TNF-R55 and TNF-R75 in the rheumatoid synovial membrane: TNF receptors are localized preferentially in the lining layer; TNF-alpha is distributed mainly in the vicinity of TNF receptors in the deeper layers. Scand J Immunol 1999: 49 (3): 278-285.
80. Robak T, Gladalska A, Stepien H. The tumor necrosis factor family of receptors/ligands in the serum of patients with rheumatoid arthritis. Eur Cytokine Netw 1998: 9: 145-154.
81. Steiner G, Studnicka-Benke A, Witzmann G, Hofler E, Smolen J. Soluble receptors for tumor necrosis factor and interleukin-2 in serum and synovial fluid of patients with rheumatoid arthritis, reactive arthritis and osteoarthritis. J Rheumatol 1995: 22 (3): 406-412.
82. Saklatvala J. Tumour necrosis factor alpha stimulates resorption and inhibits synthesis of proteoglycan in cartilage. Nature 1986: 322: 547-549.
83. Kristensen M, Chu C Q, Eedy D J, Feldmann M, Brennan F M, Breathnach S M. Localization of tumour necrosis factor-alpha (TNF-alpha) and its receptors in normal and psoriatic skin: epidermal cells express the 55-kD but not the 75-kD TNF receptor. Clin Exp Immunol 1993: 94: 354-362.
84. Beyaert R, Schulze-Osthoff K, Van Roy F, Fiers W. Synergistic induction of interleukin-6 by tumor necrosis factor and lithium chloride in mice: possible role in the triggering and exacerbation of psoriasis by lithium treatment. Eur J Immunol 1992: 22 (8): 2181-2184.
85. Bonifati C, Carducci M, Cordiali F P et al. Correlated increases of tumour necrosis factor-alpha, interleukin-6 and granulocyte monocyte-colony stimulating factor levels in suction blister fluids and sera of psoriatic patients - relationships with disease severity. Clin Exp Dermatol 1994: 19 (5): 383-387.
86. Ettehadi P, Greaves M W, Wallach D, Aderka D, Camp R D. Elevated tumour necrosis factor-alpha (TNF-alpha) biological activity in psoriatic skin lesions. Clin Exp Immunol 1994: 96 (1): 146-151.
87. Olaniran A K, Baker B S, Paige D G, Garioch J J, Powles A V, Fry L. Cytokine expression in psoriatic skin lesions during PUVA therapy. Arch Dermatol Res 1996: 288 (8): 421-425.
88. Nickoloff B J, Karabin G D, Barker J N et al. Cellular localization of interleukin-8 and its inducer, tumor necrosis factor-alpha in psoriasis. Am J Pathol 1991: 138 (1): 129-140.
89. Uyemura K, Yamamura M, Fivenson D F, Modlin R L, Nickoloff B J. The cytokine network in lesional and lesion-free psoriatic skin is characterized by a T-helper type 1 cell-mediated response. J Invest Dermatol 1993: 101 (5): 701-705.
90. Asadullah K, Prosch S, Audring H et al. A high prevalence of cytomegalovirus antigenaemia in patients with moderate to severe chronic plaque psoriasis: an association with systemic tumour necrosis factor alpha overexpression. Br J Dermatol 1999: 141 (1): 94-102.
91. Ritchlin C, Haas-Smith S A, Hicks D, Cappuccio J, Osterland C K, Looney R J. Patterns of cytokine production in psoriatic synovium. J Rheumatol 1998: 25 (8): 1544-1552.
92. Partsch G, Steiner G, Leeb B F, Dunky A, Broll H, Smolen J S. Highly increased levels of tumor necrosis factor-alpha and other proinflammatory cytokines in psoriatic arthritis synovial fluid. J Rheumatol 1997: 24: 518-523.
93. Suda T, Takahashi T, Golstein P, Nagata S. Molecular cloning and expression of the Fas ligand, a novel member of the tumor necrosis factor family. Cell 1993: 75 (6): 1169-1178.
94. Moreland L W, McCabe D P, Caldwell J R et al. Phase I/II trial of recombinant methionyl human tumor necrosis factor binding protein PEGylated dimer in patients with active refractory rheumatoid arthritis. J Rheumatol 2000: 27 (3): 601-609.
95. Moreland L W, Baumgartner S W, Schiff M H et al. Treatment of rheumatoid arthritis with a recombinant human tumor necrosis factor receptor (p75)-Fc fusion protein. New Engl J Medical 1997: 337 (3): 141-147.
96. Moreland L W, Heck J, Koopman W J. Biologic agents for treating rheumatoid arthritis: concepts and progress. Arthritis Rheum 1997: 40: 397-409.
97. Jacobi A, Manger B, Schuler G, Herd M. Therapeutic application of TNF-alpha inhibitors infliximab and etanercept in inflammatory skin disorders. J Deutschen Dermatologischen Gesellschaft 2003: 1 (4): 259-272.
98. Maini R, St Clair E W, Breedveld F et al. Infliximab (chimeric anti-tumor necrosis factor α monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial. Lancet 1999: 354: 1932-1939.
99. Maini R N, Elliott M, Brennan F M, Williams R O, Feldmann M. TNF blockade in rheumatoid arthritis: implications for therapy and pathogenesis. APMIS 1997: 105 (4): 257-263.
100. Santora L C, Krull I S, Grant K. Characterization of recombinant human monoclonal tissue necrosis factor-alpha antibody using cation-exchange HPLC and capillary isoelectric focusing. Anal Biochem 1999: 275 (1): 98-108.
101. Kempeni J. Update on D2E7: a fully human anti-tumour necrosis factor alpha monoclonal antibody. Ann Rheum Dis 2000: 59 (Suppl 1): 44-45.
102. Christen U, Thuerkauf R, Stevens R, Lesslauer W. Immune response to a recombinant human TNFR55-IgG1 fusion protein: auto- antibodies in rheumatoid arthritis (RA) and multiple sclerosis (MS) patients have neither neutralizing nor agonist activities. Hum Immunol 1999: 60 (9): 774-790.
103. 1, Ro 45-2081) in patients with rheumatoid arthritis treated for 3 months; results of an US phase II trial. Arthritis Rheum 1996: 39: S243.
104. 1, Ro 45-2081) in patients with rheumatoid arthritis treated for 3 months: results of a European phase II trial. Arthritis Rheum 1996: 39: S242.
105. 1, Ro 45-2081). Arthritis Rheum 2000: 40 (9): S224.
106. Kneer J, Luedin E, Lesslauer W, Birnboeck H, Stevens R M. An assessment of the effect of anti-drug antibody formation of the pharmacokinetics and pharmacodynamics of sTNFr55-IgG (Ro 45-2081-Lenercept [LEN]) (S.C.) in patients with rheumatoid arthritis. Arthritis Rheum 1998: 41: S58.
107. Solorzano C C, Ksontini R, Pruitt J H et al. Involvement of 26-kDa cell associated TNFa in experimental hepatitis and exacerbation of liver injury with a matrix metalloproteinase inhibitor. J Immunol 1997: 158 (1): 414-419.
108. Solorzano C C, Kaibara A, Hess P J et al. Pharmacokinetics, immunogenicity and efficacy of dimeric TNFR binding proteins in healthy and bacteremic baboon. J Appl Physiol 1998: 84 (4): 1119-1130.
109. Serono. Positive results of onercept in psoriasis and psoriatic arthritis in phase II trials. 9th International Psoriasis Symposium in New York June 2003.
110. Serono. Serono announces positive results of onercept in psoriasis and psoriatic arthritis in phase II trials. 6-22-2003. (http://www.serono.com)
111. Oh C J, Das K M, Gottlieb A B. Treatment with anti-tumor necrosis factor α (TNF-α) monoclonal antibody dramatically decreases the clinical activity of psoriasis lesions. J Am Acad Dermatol 2000: 42: 829-830.
112. Kirby B, Marsland A M, Carmichael A J, Griffiths C E. Successful treatment of severe recalcitrant psoriasis with combination infliximab and methotrexate. Clin Exp Dermatol 2001: 26 (1): 27-29.
113. Chaudhari U, Romano P, Mulcahy L D, Dooley L T, Baker D G, Gottlieb A B. Efficacy and safety of infliximab monotherapy for plaque-type psoriasis: a randomised trial. Lancet 2001: 357 (9271): 1842-1847.
114. Gottlieb A B, Masud S, Ramamurthi R et al. Pharmacodynamic and pharmacokinetic response to anti-tumor necrosis factor-alpha monoclonal antibody (infliximab) treatment of moderate to severe psoriasis vulgaris. J Am Acad Dermatol 2003: 48 (1): 68-75.
115. Gottlieb A B, Li S, Evans R, Menter A. Infliximab in the treatment of psoriasis: results from the first 10 weeks of the phase II trial. 61th Annu Meet Am Acad Dermatol (March 21-26, 2003 San Francisco).
116. Buchholz C. Promising new results reported for Remicade (infliximab) in the treatment of psoriasis. 3-1-2003. (http://www.centorcor.com).
117. Gulliver WP, Brown-Maher T, Tabrizi M. Low dose infliximab improves psoriasis. 61th Annu Meet Am Acad Dermatol (March 21-26, 2003 San Francisco).
118. Newland M R, Weinstein A, Kerdel F. Rapid response to infliximab in severe pustular psoriasis, von Zumbusch type. Int J Dermatol 2002: 41 (7): 449-452.
119. O'Quinn R P, Miller J L. The effectiveness of tumor necrosis factor alpha antibody (Infliximab) in treating recalcitrant psoriasis: a report of 2 cases. Arch Dermatol 2002: 138 (5): 644-648.
120. Cauza E, Spak M, Cauza K, Hanusch-Enserer U, Dunky A, Wagner E. Treatment of psoriatic arthritis and psoriasis vulgaris with the tumor necrosis factor inhibitor infliximab. Rheumatol Int 2002: 22 (6): 227-232.
121. Antoni C, Dechant C, Hanns-Martin Lorenz P D et al. Open-label study of infliximab treatment for psoriatic arthritis: clinical and magnetic resonance imaging measurements of reduction of inflammation. Arthritis Rheum 2002: 47 (5): 506-512.
122. Ogilvie A L, Antoni C, Dechant C et al. Treatment of psoriatic arthritis with antitumour necrosis factor-alpha antibody clears skin lesions of psoriasis resistant to treatment with methotrexate. Br J Dermatol 2001: 144 (3): 587-589.
123. Antoni C, Smolen J. The Infliximab Multinational Psoriatic Arthritis Controlled Trial (IMPACT). 61th Annu Meet J Am Acad Dermatol (March 21-26, 2003 San Francisco).
124. Mease P J, Goffe B S, Metz J, VanderStoep A, Finck B, Burge D J. Etanercept in the treatment of psoriatic arthritis and psoriasis: a randomised trial. Lancet 2000: 356 (9227): 385-390.
125. Mease P. Psoriatic arthritis: the role of TNF inhibition and the effect of its inhibition with etanercept. Clin Exp Rheumatol 2002: 20 (Suppl 28): S116.
126. Mease P J. Etanercept in psoriatic arthritis. 59th Annu Meet Am Acad Dermatol. Washington, DC 2001.
127. Gottlieb A B, Goffe B S, Burge D J, Zitnik R, Wayne T. Etanercept inhibits radiographic progression in patients with psoriatic arthritis. J Investig Dermatol 2003: 120 (7): 4-30.
128. Leonardi C, Powell J I, Matheson R. T et al. Etanercept as monotherapy in patients with psoriasis. N Engl J Med 2003: 349: 2014-2022.
129. Leonardi C, Gottlieb A B, Zitnik R. Efficacy and safety of Enbrel in patients with psoriasis: results of a phase 3 study. J Investig Dermatol 2003: 120 (7): 4-30.
130. Leonardi C L, Powers J L, Matheson R T et al. Etanercept as monotherapy in patients with psoriasis. N Engl J Med 2003: 349 (21): 2014-2022.
131. Gottlieb A B, Feng A, Zitnik R. Prolonged response durability following etanercept monotherapy. J Invest Dermatol 2003: 120 (7): 4-30.
132. Kamarashev J, Lor P, Forster A, Heinzerling L, Burg G, Nestle F O. Generalised pustular psoriasis induced by cyclosporin a withdrawal responding to the tumour necrosis factor alpha inhibitor etanercept. Dermatology 2002: 205 (2): 213-216.
133. Norris D A. Cytokine modulation of adhesion molecules in the regulation of immunologic cytotoxicity of epidermal targets. J Invest Dermatol 1990: 95 (6 Suppl.): 111S-120S.
134. Scallon B J, Moore M A, Trinh H, Knight D M, Ghrayeb J. Chimeric anti-TNF-alpha monoclonal antibody cA2 binds recombinant transmembrane TNF-alpha and activates immune effector functions. Cytokine 1995: 7 (3): 251-259.
135. Lugering A, Schmidt M, Lugering N, Panels H G, Domschke W, Kucharzik T. Infliximab induces apoptosis in monocytes from patients with chronic active Crohn's disease by using a caspase-dependent pathway. Gastroenterology 2001: 121 (5): 1145-1157.
136. Agnholt J, Kaltoft K. Infliximab downregulates interferon-gamma production in activated gut T-lymphocytes from patients with Crohn's disease. Cytokine 2001: 15 (4): 212-222.
137. Lorenz H M, Antoni C, Valerius T et al. In vivo blockade of TNF-alpha by intravenous infusion of a chimeric monoclonal TNF-alpha antibody in patients with rheumatoid arthritis. Short term cellular and molecular effects. J Immunol 1996: 156: 1646-1653.
138. Bell S, Degitz K, Quirling M, Jilg N, Page S, Brand K. Involvement of NF-[kappa]B signalling in skin physiology and disease. Cellular Signalling 2003: 15 (1): 1-7.
139. Nikolaus S, Raedler A, Kuhbacker T, Sfikas N, Folsch U R, Schreiber S. Mechanisms in failure of infliximab for Crohn's disease. Lancet 2000: 356 (9240): 1475-1479.
140. Baldwin A S Jr. The NF-kappa B and I kappa B proteins: new discoveries and insights. Annu Rev Immunol 1996: 14: 649-683.
141. Immunex Inc. Enbrel, prescribing information. 11-1-1998.
142. Mimouni D, Anhalt G J, Kouba D J, Nousari H C. Infliximab for peristomal pyoderma gangrenosum. Br J Dermatol 2003: 148 (4): 813-816.
143. Voigtlander C, Luftl M, Schuler G, Hertl M. Infliximab (anti-tumor necrosis factor alpha antibody): a novel, highly effective treatment of recalcitrant subcorneal pustular dermatosis (Sneddon-Wilkinson disease). Arch Dermatol 2001: 137 (12): 1571-1574.
144. Sullivan T P, Welsh E, Kerdel F A, Burdick A E, Kirsner R S. Infliximab for hidradenitis suppurativa. Br J Dermatol 2003: 149 (5): 1046-1049.
145. Kobbe G, Schneider P, Rohr U et al. Treatment of severe steroid refractory acute graft-versus-host disease with infliximab, a chimeric human/mouse antiTNFalpha antibody. Bone Marrow Transplant 2001: 28 (1): 47-49.
146. Humeniuk J M, Gliptis E. Infliximab in the treatment of panniculitis. World Congress Of Dermatology Paris July 1-5 2002.
147. Sacher C, Rubbert A, Konig C, Scharffetter-Kochanek K, Krieg T, Hunzelmann N. Treatment of recalcitrant cicatricial pemphigoid with the tumor necrosis factor alpha antagonist etanercept. J Am Acad Dermatol 2002: 46 (1): 113-115.
148. Henter J I, Karlen J, Calming U, Bernstrand C, Andersson U, Fadeel B. Successful treatment of Langerhans'-cell histiocytosis with etanercept. N Engl J Med 2001: 345 (21): 1577-1578.
149. Gay N J, Keith F J, Drosophila T. IL-1 receptor. Nature 1991: 351: 355-356.
150. Bozkurt B, Torre A G, Warren M S et al. Results of targeted anti-tumor necrosis factor therapy with etanercept (ENBREL) in patients with advanced heart failure. Circulation 2001: 103 (8): 1044-1047.
151. Slifman N R, Gershon S K, Lee J H, Edwards E T, Braun M M. Listeria monocytogenes infection as a complication of treatment with tumor necrosis factor alpha-neutralizing agents. Arthritis Rheum 2003: 48 (2): 319-324.
152. Lee J H, Slifman N R, Gershon S K et al. Life-threatening histoplasmosis complicating immunotherapy with tumor necrosis factor alpha antagonists infliximab and etanercept. Arthritis Rheum 2002: 46 (10): 2565-2570.
153. Netea M G, Radstake T, Joosten L A, van der Meer J W, Barrera P, Kullberg B J. Salmonella septicemia in rheumatoid arthritis patients receiving anti-tumor necrosis factor therapy: association with decreased interferon-gamma production and Toll-like receptor 4 expression. Arthritis Rheum 2003: 48 (7): 1853-1857.
154. Keane J, Gershon S, Wise R P et al. Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent. N Engl J Med 2001: 345 (15): 1098-1104.
155. Manadan A M, Mohan A K, Cote R T, Siegel J N, Sequiera W, Block J A. Tuberculosis and etanercept treatment. Arthritis Rheum 2002: 46 (Suppl): S166.
156. Georgopoulos S, Plows D, Kollias G. Transmembrane TNF is sufficient to induce localized tissue toxicity and chronic inflammatory arthritis in transgenic mice. J Inflamm 1996: 46 (2): 86-97.
157. Scallon B, Cai A, Solowski N et al. Binding and functional comparisons of two types of tumor necrosis factor antagonists. J Pharmacol Exp Ther 2002: 301: 418-426.
158. Van den Brande J M, Braat H, van den Brink G R et al. Infliximab but not etanercept induces apoptosis in lamina propria T-lymphocytes from patients with Crohn's disease. Gastroenterology 2003: 124 (7): 1774-1785.
159. van Deventer S J. Transmembrane TNF-alpha, induction of apoptosis, and the efficacy of TNF-targeting therapies in Crohn's disease. Gastroenterology 2001: 121 (5): 1242-1246.
160. Zou J, Rudwaleit M, Brandt J, Thiel A, Braun J, Sieper J. Down-regulation of the nonspecific and antigen-specific T cell cytokine response in ankylosing spondylitis during treatment with infliximab. Arthritis Rheum 2003: 48 (3): 780-790.
161. Zou J, Rudwaleit M, Brandt J, Thiel A, Braun J, Sieper J. Up regulation of the production of tumour necrosis factor alpha and interferon gamma by T cells in ankylosing spondylitis during treatment with etanercept. Ann Rheum Dis 2003: 62 (6): 561-564.
162. Ottenhoff T H, Verreck F A, Lichtenauer-Kaligis E G, Hoeve M A, Sanal O, van Dissel J T. Genetics, cytokines and human infectious disease: lessons from weakly pathogenic mycobacteria and salmonellae. Nat Genet 2002: 32 (1): 97-105.
163. Coaccioli S, Di Cato L, Marioli D et al. Impaired cutaneous cell-mediated immunity in newly diagnosed rheumatoid arthritis. Panminerva Med 2000: 42 (4): 263-266.
164. Brown S L, Greene M H, Gershon S K, Edwards E T, Braun M M. Tumor necrosis factor antagonist therapy and lymphoma development: twenty-six cases reported to the Food and Drug Administration. Arthritis Rheum 2002: 46 (12): 3151-3158.
165. C K, Borcherding S, Zhang J, Borcherding D R, Laskin D L. Edwards III The role of tumor necrosis factor-alpha (TNF-alpha) in acute and chronic inflammatory responses: novel therapeutic approaches. In: Schook L B, ed. Xenobiotic Induced Inflammation: Roles of Cytokines and Growth Factors. New York, NY: Academic Press, 1994: 97-147.
166. Decision Resources I. TNF-alpha inhibitors (Immune, Inflammatory Disorders Study # 34). Waltham, MA, Decision Resources, Inc. Immune and Inflammatory Disorders. 2001.
167. Aggarwal B B. Signalling pathways of the TNF superfamily: a double-edged sword. Nat Rev Immunol 2003: 3 (9): 745-756.
168. Wanke L A, Burge D J. Etanercept improves health-related quality of life in patients with psoriatic arthritis. 60th Annu Meet Am Acad Dermatol (February 22-27, New Orleans) 2002.
169. Lebwohl M, Gottlieb A B, Mease P J, Burge D J. Etanercept improves psoriasis activity in patients with psoriatic arthritis: results of a phase 3 multi-center clinical trial. 60th Annu Meet Am Acad Dermatol (February 22-27, New Orleans) 2003.
170. Gottlieb A B, Metheson R T, Lowe N, Zitnik R. Efficacy of Enbrel in patients with psoriasis. J Invest Dermatol 2002: 119: 234.